Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: Efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models

Journal of Immunotherapy

Volumn 36, Issue 2, 2013, Pages 102-111

  Birkhäuser, Frédéric D ^a   Koya, Richard C ^b   Neufeld, Caleb ^a   Rampersaud, Edward N ^a   Lu, Xuyang ^a   Micewicz, Ewa D ^b   Chodon, Thinle ^a   Atefi, Mohammad ^a   Kroeger, Nils ^a   Chandramouli, Gadisetti V R ^c   Li, Gang ^a   Said, Jonathan W ^d   McBride, William H ^b   Kabbinavar, Fairooz F ^a   Ribas, Antoni ^b   Pantuck, Allan J ^a   Belldegrun, Arie S ^a   Riss, Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GenEpria Consulting Inc   (United States)

Author keywords

Dendritic cell; GM CAIX; immunoediting; immunotherapy; renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; DENDRITIC CELL VACCINE; MICRORNA; MICRORNA 1186; MICRORNA 1942; MICRORNA 5097; MICRORNA 708; MICRORNA 98; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CCL1 GENE; CD209A GENE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FGL2 GENE; GENE; GENE EXPRESSION; GENETIC ENGINEERING; HMGB1 GENE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KLRA2 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES; CANCER VACCINES; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHEMOKINE CCL1; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; FIBRINOGEN; GENE EXPRESSION; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; LECTINS, C-TYPE; MICE; MICE, INBRED BALB C; MICRORNAS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY A; RECEPTORS, CELL SURFACE;

EID: 84873989235     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31827bec97     Document Type: Article

References (50)

1. Rosenberg SA. Cancer immunotherapy comes of age. Nat Clin Pract Oncol. 2005;2:115.
2. Shablak A, Hawkins RE, Rothwell DG, et al. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin Cancer Res. 2009;15: 6503-6510.
3. Gouttefangeas C, Stenzl A, Stevanovic S, et al. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother. 2007;56:117-128.
4. Swietach P, Hulikova A, Vaughan-Jones RD, et al. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene. 2010;29:6509-6521.
5. Stillebroer AB, Mulders PF, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75-83.
6. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 2011;16(suppl 2):4-13.
7. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxiainducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158:905-919.
8. Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res. 2006;12:1768-1775.
9. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24:e20-e22.
10. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX( R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol. 2011;29:121-126.
11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
12. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev. 2002;13:185-193.
13. Tso CL, Zisman A, Pantuck A, et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 2001;61:7925-7933.
14. Mukouyama H, Janzen NK, Hernandez JM, et al. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res. 2004;10:1421-1429.
15. Hernandez JM, Bui MH, Han KR, et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colonystimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res. 2003;9:1906-1916.
16. Shvarts O, Janzen N, Lam JS, et al. RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IXexpressing renal cell carcinoma. Urology. 2006;68:1132-1138.
17. Wiltrout RH, Gregorio TA, Fenton RG, et al. Cellular and molecular studies in the treatment of murine renal cancer. Semin Oncol. 1995;22:9-16.
18. Koya RC, Kimura T, Ribas A, et al. Lentiviral vectormediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther. 2007;15:971-980.
19. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models. Cary, NC: SAS Institute Inc.; 1996.
20. Klein J, Moeschberger M. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer-Verlag ISBN: 038795399X; 2003.
21. Berger RL, Boos DD. Confidence limits for the onset and duration of treatment effect. Biometrical J. 1999;41:517-531.
22. Koch KS, Son KH, Maehr R, et al. Immune-privileged embryonic Swiss mouse STO and STO cell-derived progenitor cells: major histocompatibility complex and cell differentiation antigen expression patterns resemble those of human embryonic stem cell lines. Immunology. 2006;119:98-115.
23. Daurkin I, Eruslanov E, Stoffs T, et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 2011;71:6400-6409.
24. Hoelzinger DB, Smith SE, Mirza N, et al. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol. 2010;184:6833-6842.
25. Amatschek S, Lucas R, Eger A, et al. CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer. 2011;104:469-479.
26. Oldham KA, Parsonage G, Bhatt RI, et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol. 2012;61:385-394.
27. Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. N Engl J Med. 2012;366:1156-1158.
28. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265-277.
29. Lin L, Zhong K, Sun Z, et al. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2012;138:11-22.
30. Liu H, Shalev I, Manuel J, et al. The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression. Eur J Immunol. 2008;38:3114-3126.
31. Zhou T, Chen Y, Hao L, et al. DC-SIGN and immunoregulation. Cell Mol Immunol. 2006;3:279-283.
32. Yang L, Yang H, Rideout K, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008;26:326-334.
33. Srivatsan S, Peng SL. Cutting edge: Foxj1 protects against autoimmunity and inhibits thymocyte egress. J Immunol. 2005;175:7805-7809.
34. Geiger C, Nossner E, Frankenberger B, et al. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J Mol Med (Berl). 2009;87:595-612.
35. Gays F, Aust JG, Reid DM, et al. Ly49B is expressed on multiple subpopulations of myeloid cells. J Immunol. 2006;177:5840-5851.
36. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
37. Huang V, Place RF, Portnoy V, et al. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012;40:1695-1707.
38. Ikuerowo SO, Kuczyk MA, Mengel M, et al. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer. 2006;119:867-874.
39. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res. 2006;66:6-9.
40. Farazi TA, Horlings HM, Ten Hoeve JJ, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71:4443-4453.
41. Du L, Schageman JJ, Subauste MC, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009;7:1234-1243.
42. Hu G, Zhou R, Liu J, et al. MicroRNA-98 and let-7 confer cholangiocyte expression of cytokine-inducible Src homology 2-containing protein in response to microbial challenge. J Immunol. 2009;183:1617-1624.
43. Saini S, Yamamura S, Majid S, et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 2011;71:6208-6219.
44. Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805-812.
45. Kitamura T, Hayashida K, Sakamaki K, et al. Reconstitution of functional receptors for human granulocyte/macrophage colony-stimulating factor (GM-CSF): evidence that the protein encoded by the AIC2B cDNA is a subunit of the murine GM-CSF receptor. Proc Natl Acad Sci USA. 1991;88:5 082-5086.
46. Watanabe Y, Matsumoto Y, Yamaguchi M, et al. Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and blood leukocyte dynamics following intranasal administration in rabbits. Biol Pharm Bull. 1993;16: 93-95.
47. Atkins D, Ferrone S, Schmahl GE, et al. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol. 2004;171: 885-889.
48. Chow MT, Moller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22:23-32.
49. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-1570.
50. Hino K, Fukao T, Watanabe M. Regulatory interaction of HNF1-alpha to microRNA-194 gene during intestinal epithelial cell differentiation. Nucleic Acids Symp Ser (Oxf). 2007; 415-416.